Background: The Ral guanine nucleotide-exchange factors (RalGEFs) serve as key effectors for Ras oncogene transformation of immortalized human cells. RalGEFs are activators of the highly related RalA and RalB small GTPases, although only the former has been found to promote Ras-mediated growth transformation of human cells. In the present study, we determined whether RalA and RalB also had divergent roles in promoting the aberrant growth of pancreatic cancers, which are characterized by the highest occurrence of Ras mutations. Results: We now show that inhibition of RalA but not RalB expression universally reduced the transformed and tumorigenic growth in a panel of ten genetically diverse human pancreatic cancer cell lines. Despite the apparent unimportant role of RalB in tumorigenic growth, it was nevertheless critical for invasion in seven of nine pancreatic cancer cell lines and for metastasis as assessed by tail-vein injection of three different tumorigenic cell lines tested. Moreover, both RalA and RalB were more commonly activated in pancreatic tumor tissue than other Ras effector pathways. Conclusions: RalA function is critical to tumor initiation, whereas RalB function is more important for tumor metastasis in the tested cell lines and thus argues for critical, but distinct, roles of Ral proteins during the dynamic progression of Ras-driven pancreatic cancers.
Introduction
Activating mutations of K-Ras are a hallmark of pancreatic cancer, found in as many as 30% of early-stage, dysplastic pancreatic lesions and approximately 90% of all advanced or metastatic tumors [1, 2] . K-Ras encodes a GDP-GTP-regulated binary on-off relay switch that is associated with the inner face of the plasma membrane. Ras functions as a molecular transmitter that relays the signal from extracellular stimulus-activated cell-surface receptors to diverse cytoplasmic signaling networks [3] . Mutations in the K-Ras gene leave the protein in a stimulus-independent, constitutively active GTP-bound state and thus cause persistent deregulated signaling, leading to cellular transformation [4] .
The best-characterized downstream Ras effectors are the Raf family of serine and threonine kinases that activate MEK and the ERK mitogen-activated protein kinase (MAPK) pathway. The importance of this pathway in Ras-mediated oncogenesis is supported by mutational activation of B-Raf in human cancers [5] . However, B-Raf mutations are not found in pancreatic cancers, suggesting that other effector pathways may be critical for Ras-mediated pancreatic cancer growth [6] . Consistent with this possibility, we and others found that ERK activation is not consistently seen in pancreatic cancers [7, 8] . Similarly, we found that activation of the Akt serine and threonine kinase, a key downstream target of the second major class of Ras effectors, the phosphatidylinositol 3-kinases (PI3Ks), was activated infrequently in pancreatic cancers [8] . Furthermore, mutational activation of PI3K is also not commonly seen in this cancer [9] . Thus, other effectors may be more critical for Ras-mediated development and growth of pancreatic cancers.
Recent studies support an important role for the Ral guanine nucleotide-exchange factors (RalGEFs) as key effectors of Ras-mediated growth transformation of human cells. RalGEFs serve as activators of the highly homologous Ras-like RalA and RalB small GTPases [3] . Although earlier studies of Ras transformation of rodent fibroblasts indicated RalGEFs are not particularly transforming on their own but could cooperate with the MAPK pathway to promote transformation [10] , RalGEF-Ral activation was recently found to be necessary and sufficient for Ras transformation of a variety of human cell types [11, 12] . However, despite the fact that RalA and RalB share 85% amino acid sequence identity, with 100% sequence identity in sequences important for effector binding [13] , inhibition of RalA but not RalB expression retarded the anchorage-independent soft agar of immortalized and SV40-T/t-Ag-expressing human embryonic kidney (HEK) epithelial cells expressing oncogenic H-Ras and three pancreatic cancer cell lines, suggesting that RalA may carry the brunt of the oncogenic Ras signal transmitted by RalGEFs [8] . Moreover, inhibition of RalA but not RalB also retarded the tumorigenic growth of the transformed HEK, fibrosarcoma, bladder-and colon-cancer cell lines [8] . This suggests the intriguing possibility that RalA, as opposed to RalB, may play a critical role in tumor initiation in Ras driven cancers such as pancreatic.
Other studies also suggest functional divergence of RalA and RalB. First, in vesicle transport, a constitutively activated version of RalA but not RalB promoted basolateral delivery of secretory vesicles in MDCK dog cells [14] . Second, in cell viability, transient transfection with short interfering RNA (siRNA) against RalB, but not RalA, activated programmed cell death in some [15] but perhaps not all [8, 16] human tumor cell lines when seeded in suspension but not when cells were adherent. Third, in cell proliferation, transient siRNA against RalA, but not RalB, decreased DNA synthesis of suspended cells [15] . Fourth, in cell migration, transient siRNA suppression of RalB, but not RalA, reduced UMUC-3 bladder and DU145 prostate carcinoma-cell transwell migration in vitro and normal rat kidney migration on plastic [16, 17] . Conversely, ectopic expression of constitutively active RalA inhibited migration, whereas expression of constitutively active RalB stimulated migration of the UMAC-3 and DU145 cancer cells [16] . Because RalA and RalB may serve distinct functions in cell survival and migration, we determined whether these two highly related GTPases contribute to distinct facets of the malignant-growth properties of pancreatic carcinoma cells.
Results

RalA but Not RalB Is Required for Transformed Growth of Pancreatic Cancer-Cell Lines In Vitro
To address whether RalA and RalB are functionally distinct and contribute to other facets of cancer-cell growth, we employed a retrovirus vector-based approach to stably express shRNA against RalA, RalB, or a scramble control into an expanded panel of K-Ras mutation-positive human pancreatic cancer-cell lines and then evaluated the consequence on different facets of the malignant phenotype. We focused on pancreatic carcinoma because this cancer has the highest rate of Ras mutations [4] and because continued mutant KRas function is critical for transformed and tumorigenic growth of pancreatic cancer cells [18, 19] .
To determine whether the dependency on RalA and not RalB for the anchorage-independent growth is a universal property with K-Ras mutation-positive pancreatic carcinoma cells, we stably infected the ten K-Ras mutation-positive human pancreatic cancer cell lines AsPc-1 [20] , HPAC [21] , HPAF-II [22] , Panc-1 [23] , SW1990 [24] , Capan-1 [25] , Capan-2 [26] , CFPac-1 [27] , MIA PaCa-2 [28] , and T3M4 [29] with a retrovirus encoding RalA shRNA, RalB shRNA, or a scramble control and confirmed appropriate knockdown expression of the targeted Ral protein ( Figure 1A ). Stable suppression of either RalA or RalB in each cell line had no gross effect on the morphology or the ability of the cells to proliferate in monolayer culture compared that of the scramble control counterparts (data not shown). However, stable suppression of RalA expression significantly impaired the anchorage-independent growth of nine of ten cell lines, ranging from a 55% to 90% decrease in colony numbers ( Figure 1B and see Figure S1 in the Supplemental Data available with this article online). Capan-2 cells, the one exception (data not shown), were very difficult to seed as single cells and usually aggregated in soft agar, and this may account for their apparent resistance to RalA shRNA. The observed decrease in transformation in most of the cell lines was not an off-target effect, as shown by the fact that this decrease was overcome by reintroduction of wild-type RalA into RalA knockdown Capan-1 cells ( Figure S1 ). Conversely, RalB activity did not seem to be required for anchorage-independent growth in the pancreatic cell lines tested because near-complete abrogation of RalB protein levels did not affect their ability to grow in soft agar ( Figures 1A and 1B and Figure S1 ). In fact, knockdown of RalB in the HPAC cells resulted in even greater colony numbers. Based on this comprehensive analysis of pancreatic cancer cell lines, we concluded that knockdown of RalA, but not RalB, reproducibly inhibited anchorage-independent proliferation of human pancreatic cancer cells in vitro.
RalA but Not RalB Is Required for Establishing Human Pancreatic Tumors In Vivo Although growth in suspension is a reliable in vitro assay for predicting the tumorigenic growth of human tumor cells, it is also clear that the tumor-forming capacity of a cell requires more than simply escape from anchorage dependency of growth. Moreover, although the aforementioned pancreatic carcinoma cell lines harbor mutated K-Ras, they differ in other genetic lesions (e.g., p53, DPC4 and BRCA2 tumor suppressor inactivation, p16 inactivation, and HER2 overexpression), and it is well established that Ras or effector mutants thereof can have vastly different effects depending on genotype [3] . Therefore, to determine whether RalA, and not RalB, is required for tumorigenic growth and whether such growth is influenced by other genetic parameters, each of the ten different cells line stably expressing either scramble control shRNA, RalA shRNA, or RalB shRNA were injected subcutaneously into both flanks of four immunocompromised mice per cell line. When compared to scramble control cells, loss of RalA in all ten pancreatic cancer lines both invariably prolonged the latency period of tumorigenesis by at least 2-fold and impeded subsequent tumor growth kinetics (Figures 2A-2C ). Again, this was not an off-target effect of RNAi because restoration of RalA protein level reconstituted the tumorigenic potential of RalA knockdown Capan-1 cells (Figures 2A and 2B ). On the other hand, loss of RalB had minimal or no measurable effect on tumorigenic growth in vivo (Figures 2A-2C ). We therefore conclude that RalA, but not RalB, is needed to establish the growth of K-Ras mutation-positive pancreatic tumors in vivo, independent of other genetic alterations.
RalA and RalB Are Both Required for Invasion In Vitro Despite the apparent lack of an involvement for RalB in tumor growth, transient knockdown of RalB, but not RalA, was reported to reduce cell migration of three Ras mutation-negative cell lines by w50% [16, 17] . Thus, although our studies above found that RalB was dispensable for two different growth parameters, we assessed the possibility that RalB may still be required for other aspects of malignancy. Nine pancreatic cancer cells stably expressing shRNA constructs specific to RalA, RalB, or a scramble version were seeded into invasion chambers containing reconstituted basementmembrane protein matrix. Cells that invaded toward fetal calf serum containing growth medium were quantitated after 24 hr and expressed as a percentage of scramble control cells.
Suppression of either RalA or RalB caused a significant reduction in invasion for five cell lines (Capan-1, HPAF II, T3M4, SW 1990, and MIA-PaCa-2), whereas suppression of RalB and not RalA reduced invasion for two other lines (PANC-1 and CFPac-1). This was not seen in every cell line in light of the fact that reduction of RalA enhanced migration of Panc-1 cells and suppression of RalA or RalB had no reproducible effect in Capan-2 and AsPc-1 cells (Figure 3 ). Thus, in contrast to anchorage-independent and tumorigenic growth, RalB is critical for the invasive properties of the majority (seven of nine) of pancreatic carcinoma cell lines. However, because RalA was also important for invasion for five of nine lines, it may also contribute to this malignant cell phenotype.
RalA and RalB Are Both Required for Metastatic Growth of Ras G12V -Transformed Human Cancer Cells In Vivo Because cell migration, invasion, and survival in suspension are all important components of tumor-cell metastasis [30] , we speculated that RalB might be important for pancreatic cancer-cell metastasis. In support of this possibility, expression of an activated RalGEF protein was shown to increase the metastatic growth of Ras G12V -transformed murine fibroblasts or spontaneously transformed hamster fibroblasts cells when injected into the tail vein [31, 32] .
To investigate the separate roles of RalA and RalB in metastasis, we first determined whether knockdown of RalA or RalB altered the metastatic potential of T/t-Ag + hTERT-expressing human embryonic kidney (HEK) cells transformed by oncogenic H-Ras, given that these cells have proven to be a reliable but genetically malleable model of Ras-driven tumorigenesis [33] . These cells stably expressing an shRNA against RalA, RalB, or a scramble sequence as negative control [8] were injected into tail veins of four immunocompromised mice each. The mice were monitored regularly until any of the three groups of mice manifested signs of respiratory distress or significant cachexia, at which point all mice were sacrificed and their internal organs were examined for evidence of metastasis.
Mice injected with scramble control-treated cells developed respiratory distress and cachexia at day 32, and such developments were clear indications of metastasis. Upon necropsy, the mice were found to have severe destruction and replacement of both lungs by tumor tissue ( Figure 4A ). When examined under dissection microscopy, the lung parenchyma of mice injected with scramble control cells were almost completely occupied with metastatic nodules ( Figure 4B ). Histological analysis of ten randomly chosen fields revealed that, on average, half the lung was occluded with tumor ( Figure 4C ).
As would be expected because RalA is needed for the establishment of tumors, at the time control mice exhibited physiological signs of metastasis, mice injected with RalA knockdown cells showed normal appearance and behavior. Upon gross examination of the lungs of these animals, metastatic nodules were found to be significantly less in number and also much smaller in size compared to control animals (Figures 4A). Histologically, there was more than a 2-fold decrease in tumor occlusion in the lung compared to scramble control cells ( Figures 4B and 4C , 49% versus 18%, p = 0.046).
Perhaps the most interesting observation was that despite loss of RalB expression having no effect on tumor growth of cells injected subcutaneously [8] , the very same cells injected in the tail vein were nearly incapable of metastatic tumor growth. Specifically, like RalA knockdown cells, mice injected with RalB knockdown cells showed normal appearance and behavior at the time control mice exhibited physiological signs of metastasis. This was born out at the organ level because mice injected with cells stably expressing RalB shRNA did not show any macroscopically visible metastatic nodules in the lungs ( Figure 4A ). Histological examination of the lungs did reveal some fields with tumor nodules, but this was almost 20-fold less frequent than in control mice ( Figures 4B and 4C , 3% versus 49%, p = 0.005) and 6-fold less than mice injected with RalA knockdown cells (3% versus 18%, p = 0.017). Thus, in sharp contrast to subcutaneous tumor growth of transformed HEK cells, where RalB is dispensable, RalB is critical for metastatic tumor growth of the same cell line when injected intravenously. These results suggest that instead of initiating tumorigenic growth, RalB may play an essential role in the survival of tumor cells in the bloodstream or in their extravasation into remote sites during metastasis.
RalA and RalB Are Required for Metastatic Growth of Two Human Pancreatic Cancer-Cell Lines In Vivo
To address the role of RalA and RalB in a model more reflective of human cancer, we repeated these experiments by using human pancreatic cancer-cell lines. Unlike subcutaneous tumor growth, most of the pancreatic lines tested did not grow, or did not reproducibly grow in a metastatic fashion, at least during the period of observation (up to 4 months, data not shown). Hence, we had to limit our analysis to two different metastatic human pancreatic cancer-cell lines, AsPc-1 and CFPac-1, which were derived from cancerous ascites or liver metastasis [20, 27] , respectively, and could form metastatic tumors when they were injected into the tail vein of mice.
AsPc-1 scramble control tumor cells readily formed tumor nodules in the lungs of mice after 4 weeks ( Figure 5A ). Histological analysis of the lungs revealed metastatic nodules overtaking, on average, 82% of the normal lung tissue (Figures 5B and 5C ). Knockdown of RalA or RalB ( Figure 1A ) blunted this effect with a noted decrease in macroscopic nodules and metastatic tumor growth in the lungs compared to control mice ( Figures  5A-5C , 60% versus 82%, p = 0.079; 47% versus 82%, p = 0.010, respectively). Similarly, knockdown of either RalA or RalB in CFPac-1 cells visibly reduced the tumor burden in the lungs when these cells were injected intravenously ( Figures 5D and 5E ), although this was not statistically significant (p = 0.237 and 0.126, respectively). However, these cells also metastasized to the adrenal glands, and in this organ, the reduction of tumor metastasis when RalB, but not RalA, was knocked down was almost 40-fold compared to the scramble control cells (Figures 5G-5I , 2% versus 78%, p = 0.010). Histologically, scramble control and RalA knockdown CFPac-1 cells almost completely destroyed and replaced the normal architecture of the adrenal glands, whereas the adrenal glands of mice injected with RalB-shRNAexpressing cells looked completely normal, as shown by the preservation of the three cortical zones and the medulla (Figures 5H). Cells would have to transverse through the systemic circulation after the lungs to reach the adrenal glands, and hence we speculate that the difference of metastatic potential of RalB knockdown cells between the lungs and adrenal glands may reflect the longer period of time in the bloodstream. We concluded that both RalA and RalB are required for tumor metastasis of these two cell lines when assessed by tail-vein injection but that RalB may play a more important role than RalA in this process.
RalA and RalB Are Activated in Human Pancreatic Adenocarcinoma Samples
To address the importance of RalA and RalB in pancreatic carcinoma cells in the cancer patient, we assayed the activation status of RalA and RalB as well as the other two major Ras effector pathways in pancreatic specimens from patients diagnosed with pancreatic cancer. For these analyses, we collected two normal samples with two matched tumor samples that were harvested from different sites of the surgical specimen from the same patient as well as two matched normal samples and one tumor sample from another patient, and we assayed six normal and five tumor samples each harvested from eleven other patients.
Activation of K-Ras and Ral proteins, as assayed by pull-down for the GTP-bound protein followed by immunoblotting for detecting Ras or Ral, was first measured. Ras-GTP was detected in almost all tumor samples but not in any of the normal samples, reflecting the high frequency of activating mutation of K-Ras in pancreatic cancers. RalA was also significantly activated in all tumor samples, although it was slightly activated in normal pancreatic tissue obtained from one patient (Figure 6 ). By stripping the same blot and reincubating it with RalB antibody, we found that RalB was also activated in all tumor samples. We note that RalB was more commonly activated in tumor specimens than pancreatic cancer cell lines [8] , possibly reflecting a need for RalB expression in vivo. Interestingly, the ratio of K-Ras-GTP to total K-Ras protein was lower than the ratio of RalA-GTP or RalB-GTP to total RalA or RalB in some samples. Why there is discordance between RalA and K-Ras activation is unclear but may reflect activation of RalGEFs independent of Ras [34] or by wild-type Ras. Nevertheless, activation of Ral proteins in the pancreatic cancer cells is presumably mediated to some extent by oncogenic K-Ras because knockdown of an oncogenic allele of K-Ras reduces Ral-GTP levels [8] . On the other hand, activation of the MAPK and PI3K-Akt pathways, as assayed by phospho-ERK1/2 and phospho-Akt, respectively, were infrequently activated and seen in both normal and tumor samples. Thus, despite the presence of K-Ras activation in these pancreatic cancer specimens, RalA and RalB, and not ERK or AKT, were the most commonly activated proteins downstream of Ras. Collectively, these studies suggest an important role for Ral activation in oncogenic properties of pancreatic cancers.
Discussion
Recent studies in a mouse model [35] and cell culture [11, 12] implicate the importance of the RalGEF-Ral effector pathway in mediating Ras oncogenesis. RalGEFs activate two highly related targets, RalA and RalB. Although RalA and RalB share significant sequence (85%) and biochemical identity and interact with common effectors, there is growing evidence for their distinct roles in promoting Ras-mediated malignant transformation. However, a rigorous evaluation of RalA and RalB function in Ras mutation-positive human cancers has not been done. Because 90% of pancreatic cancers harbor mutant Ras and mutant Ras is critical for the transformed and tumorigenic growth of this cancer type, we chose to determine whether RalA and RalB serve redundant or distinct roles in Ras-mediated oncogenesis. We now demonstrate that RalA, and not RalB, is critical for anchorage-independent growth in vitro and tumorigenic growth in vivo. In striking contrast, RalB, and to a lesser degree RalA, is needed for cell invasion in vitro in seven and five pancreatic cancer cell lines assayed, respectively, and for metastatic growth in vivo as assessed by tail-vein injection of three different tumorigenic cell lines tested. Finally, we demonstrate that both RalA and RalB are aberrantly activated in pancreatic tumor tissue. Our results support unique roles for otherwise highly related Ral GTPases in very distinct stages of tumor progression and growth.
In regards to RalA, the universal dependency specifically on this protein for transformation and tumorigenesis is particularly poignant given the genetic diversity of the ten pancreatic carcinoma cell lines. Although all possess mutationally activated K-Ras, they are divergent in their origins and in their genetic profiles [36] . What cellular phenotype RalA promotes in tumor growth remains to be determined, but transient knockdown of the protein has been found to decrease the rate of DNA synthesis in a variety of tumor cells placed in suspension [15] .
As opposed to RalA, RalB was uniformly dispensable for transformed and tumorigenic growth. However, there was a strong dependency on RalB for pancreatic carcinoma cell invasion in vitro, and transient knockdown of RalB can induce apoptosis of some cells when put in suspension [15] . As such, perhaps it is not surprising that a role for RalB in tumorigenesis in vivo was not uncovered until the cells were put in a similar situation, such as metastasis, during which cells must survive in suspension in the circulatory system and display altered cell-adhesion properties for adhering to and invading heterologous tissue, etc. Despite the fact that RalB is important for cell invasion and survival is a possible lead on the role of RalB in metastasis, this still must be further defined because knockdown of RalB in AsPc-1 cells had no effect on cell migration but did inhibit metastasis. Although our observations support multiple functions for RalB in facilitating the spectrum of cellular changes needed for metastatic growth, this is not to say that RalA plays no role in metastasis. Knockdown of RalA could suppress cell migration in vitro, and as one would expect because RalA is required for tumor initiation, knockdown of RalA also impeded tumor metastasis but to a lesser extent than that of RalB. Thus, although both RalA and RalB contribute to malignant processes, they may contribute to distinct facets and serve nonredundant functions in pancreatic tumor cell invasion and metastasis.
This division of labor presumably reflects different pathways engaged by these two nearly identical small GTPases. How this occurs is still unknown because both proteins bind to similar effectors [34] , but three models are envisioned. First, RalA and RalB have different subcellular localizations [8, 14] , and hence engagement of effectors in different subdivisions of the cell may underlie their different effects on tumorigenesis. Evidence for this possibility is supported by recent observations that spatial differences in Ras localization results in utilization of distinct effectors [8, 14] , and a differential association of RalA and RalB with endomembranes, specifically endosomes, has been described [14] . Second, RalA and RalB may bind effectors with different affinities. In this case, however, it is still unclear as to the extent varied affinities for effectors may have on Ral signaling. Whereas RalA was found to display greater binding affinity for the exocyst complex [14] , RalB has been argued to preferentially utilize the exocyst to promote cell motility [17] . Third, although RalA and RalB share complete sequence identity in the effector domain and switch I and II sequences (residues 36-56 and 70-87, respectively), they do diverge in sequences immediately upstream of switch II (residues 91-153; 48% identity) [14] . Thus, it remains possible that RalA and RalB may utilize distinct effectors that account for their divergent roles in malignant growth.
Studies of Ras transformation in experimental rodentmodel cell systems, together with the identification of mutationally activated and transforming alleles of BRaf [5] and the p110a subunit of PI3K [9] , have argued that the Raf-MEK-ERK and PI3K-Akt effector pathways are the most crucial signaling mechanisms for Ras-mediated oncogenesis. It was thus surprising to find that persistent activation of ERK or Akt was not consistently seen in the majority of patient tumors. Although a lack of ERK [7, 8] and Akt [8] activation has been noted in pancreatic cancer cell lines, the facts that this was borne out in human tumor specimens and that instead RalA and RalB are consistently activated suggests that aberrant activation of the RalGEF-Ral pathway may be more important than either the Raf or PI3K effector pathways in the growth of this cancer type. Indeed, mutational activation of either B-Raf or p110a is infrequent in pancreatic cancers [6, 9] . Our suggestion that the RalGEFRal pathway is crucial for pancreatic cancer growth emphasizes an emerging concept, in which the oncogenic functions of Ras will be mediated by distinct, tissuetype-specific, signaling pathways [11, 12] . These results also argue that anti-Ras strategies that target specific Ras effector signaling pathways may require cancerspecific approaches. For example, inhibitors of Raf and MEK are currently under evaluation in phase I and II clinical trials [37] . We thus speculate that these inhibitors may not be the most effective approach for pancreatic cancer treatment, and instead, approaches to target the RalGEF-Ral pathway may be needed.
In summary, our study establishes the important contribution of aberrant Ral GTPase activation in multiple facets of Ras mutation-positive pancreatic tumor-cell growth. Furthermore, we found that RalA and RalB activation contribute to very distinct facets of tumor-cell progression and growth. Thus, consistent with the dynamic nature of cancer and the clear involvement of Ras at many different stages of cancer, it appears that Ral GTPases are needed through different stages of cancer progression. Targeting the distinct functions of Ral GTPases could thus hold promise as a strategy for treating pancreatic cancers.
Experimental Procedures
Human Pancreatic Cancer-Cell Lines Human pancreatic cancer-cell lines, AsPc-1 [20] , HPAC [21] , HPAF-II [22] , PANC-1 [23] , SW1990 [24] , Capan-1 [25] , Capan-2 [26] , CFPAC-1 [27] , MIA Paca-2 [28] , and T3M4 [29] were purchased from ATCC or provided by M. Korc and maintained in accordance with ATCC's recommendations.
Human Pancreatic Cancer Samples
Matched and unmatched frozen surgical samples of normal human pancreatic tissues and pancreatic adenocarcinomas were provided by Dr. A.D. Proia and Dr. D. Tyler (Duke University Medical Center) and histologically verified to be pancreatic adenocarcinoma by board-certified pathologists.
Plasmids and Creation of Stable Cell Lines
Retroviruses derived from pSuper-Retro-Puro plasmids encoding shRNA against RalA, RalB, or a scramble sequence, pBabeBlasti encoding siRNA-resistant wild-type RalA [8] , were used for stable infection of the indicated cell lines and thus yielded mass populations of puromycin-resistant cells, as previously described [38] . Detection of activated GTP-bound K-Ras, RalA, and RalB via association with effector protein domains specific for activated version of these proteins followed by immunoblot analysis with antibodies specific for K-Ras, RalA, or RalB, respectively in a panel of 18 matched or unmatched pancreatic tissue samples obtained from patients. Detection of MAPK and PI3K activation in the same cell lines by immunoblot analysis with phosphospecific antibodies for phosphorylated forms of ERK1/2 (P-ERK1/2) and Akt (P-Akt), respectively. Total K-Ras, RalA, RalB, ERK1/2, and Akt or actin serve as loading controls. (''N'' represents normal tissue; ''T'' represents adenocarcinoma tissue).
Immunoblotting
The described cell lines were collected from nearly confluent 10 cm plates and lysed in 150 ml freshly made cold general lysis buffer (25 mM Tris [pH 7.4], 150 mM NaCl, 5 mM EDTA, 1% Triton-X, 1 mg/ml pepstatin A, 1 mg/ml leupeptin, 1.5 mg/ml aprotinin, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mM Na 3 VO 4, 1 mM NaF, and 1 mM DTT) for 10 min. To test for activation of Ras and the ERK MAPK, PI3K, and Ral pathways, we cultured the indicated cells in growth medium supplemented with 0.5% FBS for 48 hr. Frozen surgical pancreatic tissue samples were ground with pestle and mortar, incubated on ice with buffer (50 mM Tris [pH 7.5], 200 mM NaCl, 10 mM MgCl 2, 1% NP40, 1% aprotinin, 1 mM PMSF, and 0.5 mM DTT), and then passed through a 21-gauge needle.
For immunoblot analyses, 100 mg of the lysates were resolved in a 12.5% SDS-PAGE gel, transferred to PVDF membrane (Millipore), and incubated with the following antibodies diluted according to the manufacturer's recommendation: a-actin (Santa Cruz), a-RalA and a-RalB We assayed levels of endogenous activated Ral-GTP or Ras-GTP as described previously [39, 40] by incubating cell lysates with glutathione-agarose bound recombinant glutathione S-transferase fusion proteins containing the GTP-dependent binding domains (BD) of the Ral or Ras proteins GST-RalBD or GST-RafBD. Total Ral or K-Ras, RalA-GTP, RalB-GTP, and K-Ras-GTP levels were then detected by SDS-PAGE and immunoblotting with the aforementioned anti-RalA, anti-RalB or anti-K-Ras. We determined total Ral or K-Ras levels by immunoblotting untreated lysates with the same antibody.
Cell-Proliferation Assay in Monolayer Culture
Cell lines were trypsinized so that single-cell suspensions could be generated, 10 4 cells per 6 cm dishes were seeded, and viable (trypan-blue-negative) cells were counted daily for 6 days.
Soft-Agar Assay
Five thousand cells per 3 cm plate were suspended in soft agar as described [11, 41] and colonies greater than 30 cells were scored after 3-4 weeks. Assays were done in triplicate and three times independently.
In Vitro Invasion Assay Log-phase cell lines were incubated in serum-free medium for 24 hr. Growth-factor-reduced Matrigel invasion chambers (BD BioCoat BD Matrigel Invasion 24-well Chamber, 8 mm pore, BD Biosciences) were then rehydrated for 2 hr at 37 C with serum-free medium and immediately prior to the addition of dissociated cells to the upper chamber (5 3 10 4 of Panc1, 10 5 all others), 10% v/v of FCS was added to the lower chamber. After 24 hr, Matrigel and uninvaded cells were removed from the upper chamber with a moistened cotton swab. Invaded cells on the bottom of the membrane were fixed and stained with the Diff-Quik kit (Baxter Scientific). After drying overnight, stained cells were counted under microscopy.
Xenograft Tumorigenesis Assay
Ten million cells of the indicated cell lines were mixed with Matrigel and injected subcutaneously into both flanks of immunocompromised SCID/Beige mice (Charles River Laboratory) of two mice. Tumor volumes were determined approximately twice per week and calculated as 1/2 length 2 3 width in unit of mm 3 . Xenograft experiments were reviewed and approved by the Duke University Institutional Animal Care and Use Committee.
Metastasis Assay by Tail-Vein Injection
One million cells of the indicated lines were resuspended in 200 ml of sterile PBS and injected via tail vein into four mice. Mice were monitored periodically for signs of weight loss, hair loss, respiratory distress, and general malaise. Upon detection of any of these parameters in a single mouse of a treatment group, all mice were euthanized and necropsied. In mice injected with HEK-HT-Ras G12V , AsPc-1, or CFPAC-1-derived cell lines, this occurred at 32 days, 28 days or 95 days after injection, respectively. Metastasis experiments were reviewed and approved by the Duke University Institutional Animal Care and Use Committee. A Student's t test was used for assessing the significance of tumor burden in lung fields between mice injected with experiment compared to control cells.
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